Business
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n \n \n \n InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n InMed's\n \n Michael Woudenberg\n \n ,\n \n Karen Long\n \n & Prof.\n \n Mauro Maccarrone\n \n among Expert Speakers\n \n \n \n \n VANCOUVER, BC\n \n ,\n \n Jan. 19, 2021\n \n /CNW/ -\n \n InMed Pharmaceuticals Inc.\n \n (\"InMed\" or the \"Company\") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (\"CBN\"), today announced that executives of the Company will speak at the 2021\n \n Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe\n \n (\"CDP Europe\"). CDP Europe will be held virtually from\n \n January 19-21, 2021\n \n .\n \n Michael Woudenberg\n \n - Vice President, Chemistry, Manufacturing & Controls,\n \n Karen Long\n \n - Senior Director, Drug Development, and Prof. Mauro Maccarrone PhD - Scientific Advisor to InMed will all be featured as expert speakers at the event.\n \n \n Mr.\n \n Michael Woudenberg\n \n will participate on a panel discussion on the topic of \"\n \n Comparing Whole Plant & Synthetic Cannabinoids & Their Potential in Pharmaceuticals\n \n \" which will cover topics including the availability of cannabinoids in both whole plant and synthetic systems, the biggest trade-off between plant-derived and synthetic compounds and comparing cost advantages in the short and long term.\n \n \n Ms.\n \n Karen Long\n \n will participate on a panel discussion on the topic of \"\n \n The\n \n \n Industry Approach to Gaining Drug Approval\n \n \" to compare the differences in gaining drug approval around the world including a discussion of case studies.\n \n \n In addition, Prof.\n \n Mauro Maccarrone\n \n , a member of InMed's Scientific Advisory Board and Professor and Chair of Biochemistry, Department of Biotechnological and Applied Clinical Science...